Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Nicolas Paquette-Lamontagne_2023
Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis
Shots:  Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting     Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials  This interview…
February 13, 2023
VIEWPOINTS_Dr. Philip M. Toleikis_2023
Dr. Philip M. Toleikis, President & CEO at Sernova Shares Insights on the Partnership with Evotec to Develop a ‘Functional Cure’ for Diabetes
Shots:  Dr. Philip shared his views on the collaboration of Sernova with Evotec for iPSC-Based Beta cell replacement therapy to develop and commercialize a ‘Functional Cure’ for diabetes.   He also gave an overview on the benefits of Evotec’s iPSC-based insulin-producing beta cells on the next generation of Sernova’s Cell Pouch System  The interview discusses about how Sernova…
February 7, 2023
VIEWPOINTS_John Gabrielson_2023
John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs
Shots:  John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023
VIEWPOINTS_Dr. Jeff Cleland_2023
Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME
Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…
January 3, 2023
Viewpoints_Michael Irizarry
Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC
Shots: Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC) Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemab The interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
December 14, 2022
Load more